Table 4.

Distribution of combined genotypes of the g.32373708 G>A-IRP1 and g.49520870 G>A-IRP2 polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with AMD as well as its dry and wet forms and individuals without visual disturbances (controls)

Genotype	Controls (n = 79)	AMD (n = 254)	Crude OR (95% CI)	Adjusted ORa (95% CI)	Dry AMD (n = 99)	Crude OR (95% CI)	Adjusted ORa (95% CI)	Wet AMD (n = 155)	Crude OR (95% CI)	Adjusted ORa (95% CI)
	Number (frequency)	Number (frequency)			Number (frequency)			Number (frequency)
G/G–G/G	6 (0.07)	38 (0.15)	2.14 (0.87–5.27)	2.94 (0.91–9.55)	17 (0.17)	2.52 (0.94–6.74)	4.46 (1.21–16.41)	21 (0.13)	1.90 (0.74–4.91)	2.03 (0.55–7.56)
G/G–G/A	5 (0.06)	45 (0.18)	3.19 (1.22–8.34)	3.52 (1.20–10.30)	14 (0.14)	2.44 (0.84–7.09)	3.22 (0.91–11.40)	31 (0.20)	3.70 (1.38–9.93)	3.05 (1.01–9.37)
G/G–A/A	7 (0.09)	14 (0.05)	0.60 (0.23–1.54)	1.05 (0.30–3.67)	4 (0.04)	0.43 (0.12–1.54)	1.14 (0.26–5.08)	10 (0.06)	0.71 (0.26–1.94)	1.01 (0.25–4.07)
G/A–G/G	25 (0.32)	36 (0.14)	0.36 (0.21–0.64)	0.23 (0.10–0.51)	15 (0.15)	0.39 (0.19–0.80)	0.26 (0.09–0.68)	21 (0.13)	0.34 (0.17–0.65)	0.25 (0.11–0.61)
G/A–G/A	23 (0.30)	40 (0.16)	0.46 (0.25–0.82)	0.48 (0.22–1.04)	17 (0.17)	0.50 (0.25–1.03)	0.51 (0.19–1.36)	23 (0.15)	0.42 (0.22–0.82)	0.51 (0.21–23)
G/A–A/A	7 (0.09)	12 (0.05)	0.51 (0.20–1.34)	1.25 (0.37–4.15)	4 (0.04)	0.43 (0.12–1.53)	0.75 (0.15–3.82)	8 (0.05)	0.56 (0.19–1.60)	1.55 (0.42–5.75)
A/A–G/G	3 (0.04)	31 (0.12)	3.52 (1.05–11.85)	2.38 (0.51–11.16)	12 (0.12)	3.49 (0.95–12.84)	2.48 (0.46–13.24)	19 (0.12)	3.54 (1.01–12.35)	2.40 (0.47–12.40)
A/A–G/A	2 (0.02)	31 (0.12)	5.35 (1.25–22.90)	3.78 (0.81–17.60)	14 (0.14)	6.34 (1.39–28.80)	3.12 (0.55–17.55)	17 (0.11)	4.74 (1.06–21.07)	4.30 (0.86–21.06)
A/A–A/A	1 (0.01)	7 (0.03)	2.21 (0.27–18.25)	0.23 (0.01–6.41)	2 (0.02)	1.61 (0.14–18.01)	–	5 (0.03)	2.60 (0.30–22.64)	0.45 (0.02–11.61)

Significant ORs are in bold; –, not estimated

^aOR adjusted for age, sex, AMD in family